Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report

In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy, and first-line chemotherapy. In August 2015, appe...

Descripción completa

Detalles Bibliográficos
Autores: ARIAS RON, DAVID, LABANDEIRA GUERRA, CARMEN MARIA, Areses Manrique, María Carmen, SAMPEDRO DOMARCO, PAULA, Abdulkader Nallib, Ihab, García Mata, Jesús, Rolfo, C., Gonzalez-Rivas, D., Firvida Perez, Jose Luis
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/15725
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743439/pdf/fonc-09-00819.pdf
https://www.ncbi.nlm.nih.gov/pubmed/31552167
http://hdl.handle.net/20.500.11940/15725
Access Level:acceso abierto
Palabra clave:CHUS
CHUO
CHUVI
id ES_94a36f9bb2ef5209a7a67e69a68b23c6
oai_identifier_str oai:runa.sergas.gal:20.500.11940/15725
network_acronym_str ES
network_name_str España
repository_id_str
spelling Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case ReportARIAS RON, DAVIDLABANDEIRA GUERRA, CARMEN MARIAAreses Manrique, María CarmenSAMPEDRO DOMARCO, PAULAAbdulkader Nallib, IhabGarcía Mata, JesúsRolfo, C.Gonzalez-Rivas, D.Firvida Perez, Jose LuisCHUSCHUOCHUVIIn a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy, and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumor growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects. High expression PD-L1 level (100%) was found in the pathological tissue sample. Nivolumab was maintained for more than 2 years and stopped in December 2017 after 28 months of treatment, with no disease evidence. More than 3 years after its onset, the patient maintains an outstanding PS with complete tumor response and no evidence of disease in last surveillance CT scan and brain MRI.2019info:eu-repo/semantics/articlehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743439/pdf/fonc-09-00819.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/31552167http://hdl.handle.net/20.500.11940/15725reponame:RUNA. Repositorio da Consellería de Sanidade e Sergasinstname:Servizo Galego de Saúde (SERGAS)Ingléshttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:runa.sergas.gal:20.500.11940/157252026-06-12T08:40:47Z
dc.title.none.fl_str_mv Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
title Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
spellingShingle Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
ARIAS RON, DAVID
CHUS
CHUO
CHUVI
title_short Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
title_full Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
title_fullStr Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
title_full_unstemmed Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
title_sort Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
dc.creator.none.fl_str_mv ARIAS RON, DAVID
LABANDEIRA GUERRA, CARMEN MARIA
Areses Manrique, María Carmen
SAMPEDRO DOMARCO, PAULA
Abdulkader Nallib, Ihab
García Mata, Jesús
Rolfo, C.
Gonzalez-Rivas, D.
Firvida Perez, Jose Luis
author ARIAS RON, DAVID
author_facet ARIAS RON, DAVID
LABANDEIRA GUERRA, CARMEN MARIA
Areses Manrique, María Carmen
SAMPEDRO DOMARCO, PAULA
Abdulkader Nallib, Ihab
García Mata, Jesús
Rolfo, C.
Gonzalez-Rivas, D.
Firvida Perez, Jose Luis
author_role author
author2 LABANDEIRA GUERRA, CARMEN MARIA
Areses Manrique, María Carmen
SAMPEDRO DOMARCO, PAULA
Abdulkader Nallib, Ihab
García Mata, Jesús
Rolfo, C.
Gonzalez-Rivas, D.
Firvida Perez, Jose Luis
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv CHUS
CHUO
CHUVI
topic CHUS
CHUO
CHUVI
description In a patient who had been diagnosed of located squamous cell lung carcinoma, pneumonectomy, and adjuvant chemotherapy were performed. Brain recurrence and subsequent lung metastatic disease were uncontrolled by neurosurgery, holocranial radiotherapy, and first-line chemotherapy. In August 2015, appearance of leptomeningeal carcinomatosis triggered severe clinical deterioration and threatened the patient's life. Anti-PD1 immune checkpoint inhibitor Nivolumab was initiated in an attempt to stop tumor growth, achieving a spectacular brain and pulmonary complete response and clinical improvement, without serious adverse effects. High expression PD-L1 level (100%) was found in the pathological tissue sample. Nivolumab was maintained for more than 2 years and stopped in December 2017 after 28 months of treatment, with no disease evidence. More than 3 years after its onset, the patient maintains an outstanding PS with complete tumor response and no evidence of disease in last surveillance CT scan and brain MRI.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743439/pdf/fonc-09-00819.pdf
https://www.ncbi.nlm.nih.gov/pubmed/31552167
http://hdl.handle.net/20.500.11940/15725
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743439/pdf/fonc-09-00819.pdf
https://www.ncbi.nlm.nih.gov/pubmed/31552167
http://hdl.handle.net/20.500.11940/15725
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:RUNA. Repositorio da Consellería de Sanidade e Sergas
instname:Servizo Galego de Saúde (SERGAS)
instname_str Servizo Galego de Saúde (SERGAS)
reponame_str RUNA. Repositorio da Consellería de Sanidade e Sergas
collection RUNA. Repositorio da Consellería de Sanidade e Sergas
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413710548697088
score 15,300724

Similares en LA Referencia